Synergistic MicroRNA Therapy in Liver Fibrotic Rat Using MRI‐Visible Nanocarrier Targeting Hepatic Stellate Cells

Liver fibrosis, as one of the leading causes of liver‐related morbidity and mortality, has no Food and Drug Administration (FDA)‐approved antifibrotic therapy yet. Although microRNA‐29b (miRNA‐29b) and microRNA‐122 (miRNA‐122) have great potential in treating liver fibrosis via regulating profibroti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jun, Huang, Jinsheng, Kuang, Sichi, Chen, Jingbiao, Li, Xiaoxia, Chen, Bin, Wang, Jin, Cheng, Du, Shuai, Xintao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402399/
https://www.ncbi.nlm.nih.gov/pubmed/30886803
http://dx.doi.org/10.1002/advs.201801809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402399/
https://www.ncbi.nlm.nih.gov/pubmed/30886803
http://dx.doi.org/10.1002/advs.201801809

Ejemplares similares